About the Company
pulmatrix is a clinical stage biotechnology company with an inhaled dry powder platform advancing a new generation of inhaled therapeutics. the platform, called isperse (inhaled small particles easily respirable and emitted), represents a new paradigm in inhaled drug delivery based on unique properties: dense, high drug load engineered particles with highly efficient dispersibility and delivery to the airways. the isperse powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $PULM News
Pulmatrix Inc PULM
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Pulmatrix, Inc. (PULM) Stock Historical Prices & Data - Yahoo Finance
*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Pulmatrix, Inc. (PULM) interactive stock chart – Yahoo Finance
Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous ...
Pulmatrix Inc (2PU.DU)
*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
ARCH Venture Partners VII, L.P.'s Net Worth
Who is ARCH Venture Partners VII, L.P.? ARCH Venture Partners VII, L.P. has an estimated net worth of $671 Million. This is based on reported shares across multiple companies, which include AGIOS ...
CVKD Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart ...
Snap Inc Class A
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Pulmatrix Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Pulmatrix Inc.
Repurchase of Common & Preferred Stk. Repurchase of Common & Preferred Stk.
Loading the latest forecasts...